Biogen Q2 revenue rises 18% with Avonex sales boost
This article was originally published in Scrip
Executive Summary
Biogen Idec exceeded stock market expectations by nearly $100 million when it reported second quarter 2012 revenue of $1.4 billion – an 18.1% jump on a year-over-year basis – due in large part to a sales spike for the multiple sclerosis (MS) drug Avonex (Interferon beta-1a).